公开(公告)号：JPH0317078A

公开(公告)日：1991-01-25

申请号：JP13553790

申请日：1990-05-28

Applicant: BASF AG

Inventor： KAARUUHAINTSU GAISU ,  KURAUSU RIYUUPUZAAMEN ,  MARUCHIN TORAUTO

IPC: A61K31/47 ,  A61P1/04 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14

公开(公告)号：JPH02279672A

公开(公告)日：1990-11-15

申请号：JP6449190

申请日：1990-03-16

Applicant: BASF AG

Inventor： KAARUUHAINTSU GAISU ,  KURAUSU RIYUUPUZAMEN ,  MARUCHIN TORAUTO

IPC: A61K31/47 ,  A61K31/475 ,  A61P1/00 ,  A61P1/04 ,  A61P29/00 ,  C07D215/42

公开(公告)号：JPH01230519A

公开(公告)日：1989-09-14

申请号：JP32485288

申请日：1988-12-24

Applicant: BASF AG

Inventor： DEIITAA HERU ,  TOOMASU DERUPAA ,  ROOTAA DAUMU ,  KAARUUHAINTSU GAISU ,  AKIMU MERAA

IPC: C08B37/10 ,  A61K20060101 ,  A61K31/715 ,  A61P31/12

Abstract: PURPOSE: To obtain a medicine for preventing and treating diseases caused by retroviruses by using polysulfated heparin. CONSTITUTION: Polysulfated heparin having a sulfur content of 13-15% or its salt as an active ingredient, a known preparation carrier, a known excipient, etc., are compounded and subsequently prepared into the objective preparation by a conventional method. The preparation may be prepared in the form of tablets, capsules, powder, granules, injection agents, sprays, etc. The active ingredient is administered orally at a dose of 10-1000mg/Kg or parenterally at a dose of 0.1-10mg/Kg. The polysulfated heparin is obtained by converting heparin into the corresponding pyridinium salt and subsequently polysulfating the pyridinium salt with chlorosulfonic acid in pyridine.

公开(公告)号：JPH01275532A

公开(公告)日：1989-11-06

申请号：JP5805589

申请日：1989-03-13

Applicant: BASF AG

Inventor： ROOTAA DAUMU ,  TOOMASU DERUPAA ,  KAARUUHAINTSU GAISU ,  DEETAA HERU ,  EERITSUHI SHIYURITSUKU

IPC: C12N9/99 ,  A61K31/505 ,  A61K31/52 ,  A61K31/715 ,  A61K38/00 ,  A61K38/19 ,  A61K38/21 ,  A61K39/395 ,  A61K45/06 ,  A61P31/12 ,  A61P37/00 ,  A61P43/00

Abstract: PURPOSE: To obtain a medicine for preventing or treating diseases developed by retrovirus, by combining polysulfated heparin with a reverse transcriptase inhibitory substance so as to synergistically potentiate the inhibition of retrovirus replication. CONSTITUTION: This medicine is a combination of polysulfated heparin (pref. sulfur content: 13-16wt.%, molecular weight: 2,000-200,000) with at least one kind selected from (A) reverse transcriptase inhibitory substances such as 3'- azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine, (B) inhibitory substances for retrovirus against binding to host cells (e.g. diphenylhydantoin, monoclonal antibody to T4 -receptor (e.g. OKT4 )), (C) virus biosynthesis inhibitory substances such as avarol and avarone, (D) lymphokines having antiviral activity such as interferon β and tumor necrosis factor a and (E) retinoids such as retinol and all-trans-retinoic acid.

公开(公告)号：JPS5780358A

公开(公告)日：1982-05-19

申请号：JP13868681

申请日：1981-09-04

Applicant: Basf Ag

Inventor： GERUHARUTO KASUTONAA ,  HARUDOO JIIGERU ,  KAARUUHAINTSU GAISU

IPC: C07D317/58 ,  A61K31/275 ,  A61K38/11 ,  C07C20060101 ,  C07C67/00 ,  C07C253/00 ,  C07C255/00 ,  C07C255/42 ,  C07C255/43 ,  C07C255/58 ,  C07D317/48 ,  C07D317/60 ,  C07D317/62

CPC classification number: C07C255/00

公开(公告)号：JPS5668654A

公开(公告)日：1981-06-09

申请号：JP13452280

申请日：1980-09-29

Applicant: BASF AG

Inventor： WARUTAAABUIIRANTO BUIIRUSUDORU ,  KAARUUHAINTSU GAISU ,  HAARARUTO WAIFUENBASOHA ,  UORUFUGANGU UORUSUTOMAN ,  DEIITAA RENKE ,  RORUFU KURETSUCHIYUMAA

IPC: A61K31/27 ,  A61K31/325 ,  A61K31/34 ,  A61K31/341 ,  A61K31/357 ,  A61K31/38 ,  A61K31/381 ,  A61P25/20 ,  C07C45/62 ,  C07C45/69 ,  C07C45/75 ,  C07C45/79 ,  C07C45/81 ,  C07C49/21 ,  C07C49/337 ,  C07C49/345 ,  C07C49/543 ,  C07C49/553 ,  C07C49/573 ,  C07C67/00 ,  C07C68/02 ,  C07C68/06 ,  C07C69/96 ,  C07C239/00 ,  C07C271/06 ,  C07C271/08 ,  C07C313/00 ,  C07C319/20 ,  C07C323/43 ,  C07D307/14 ,  C07D307/22 ,  C07D307/52 ,  C07D309/04 ,  C07D309/14 ,  C07D317/28 ,  C07D319/06 ,  C07D333/20